ArticlePhysiological reports2025
Myostatin antisense administration prevents sepsis-induced muscle atrophy and weakness in male mice.
Article in Physiological reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Myostatin antisense administration prevents sepsis-induced muscle atrophy and weakness in male mice.Physiological reports · 2025Article
- Utility of Plasma Myostatin as a Predictive Biomarker for Post Intensive Care Syndrome in Patients With Sepsis.Acute medicine & surgeryArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Muscle atrophy and weakness are serious problems associated with sepsis. However, only a few pharmacological interventions are available to date. In this study, myostatin antisense was used to prevent sepsis-induced muscle atrophy and weakness. Sepsis was induced in 8-week-old male C57BL/6J mice via intraperitoneal injection of 1 mg/g cecal slurry (CS). Myostatin antisense was injected into the right tibialis anterior muscle. Myostatin mRNA was measured in the tibialis anterior and quadriceps femoris muscles on Day 1. The body weight, grip strength, and cross-sectional area of the tibialis anterior muscle were measured on Day 6. The administration of myostatin antisense decreased myostatin expression on Day 1 in the injected side (0.023 ± 0.010 in CS vs. 0.008 ± 0.002 in CS + antisense) as well as in the noninjected muscles. It also decreased the myostatin protein level (2.0 ± 0.3 in CS vs. 1.2 ± 0.5 in CS + antisense, p = 0.04). Body weight reduction (94.9% ± 2.0% vs. 98.2% ± 1.8%, p < 0.01) and grip strength reduction (77.0% ± 12.3%vs. 89.8% ± 8.3%, p = 0.04) were suppressed by the injection. The cross-sectional area of the right tibialis anterior muscle increased after the treatment (1116 ± 530 μm
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.